FWL Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

FWL Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.4K	Hold	30	–	–	﹤0.01%	243
2025 Q4	$13.6K	Hold	30	–	–	﹤0.01%	249
2025 Q3	$11.7K	Hold	30	–	–	﹤0.01%	237
2025 Q2	$13.4K	Sell	30 -15	-33%	-$6.91K	﹤0.01%	212
2025 Q1	$21.8K	Sell	45 -15	-25%	-$6.99K	0.01%	188
2024 Q4	$24.2K	Hold	60	–	–	0.01%	192
2024 Q3	$27.9K	Hold	60	–	–	0.01%	157
2024 Q2	$28.1K	Buy	60 +15	+33%	+$6.51K	0.01%	141
2024 Q1	$18.8K	Hold	45	–	–	0.01%	139
2023 Q4	$18.3K	Buy	+45	New	+$16.6K	0.01%	135

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

FWL Investment Management's VRTX Position: Q1 2026 in Review

FWL Investment Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 30 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #243.

FWL Investment Management first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $28.1K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

FWL Investment Management held 30 shares of Vertex Pharmaceuticals worth $13.4K as of Q1 2026.
FWL Investment Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of FWL Investment Management's portfolio in Q1 2026, its #243 holding.
FWL Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
FWL Investment Management's Vertex Pharmaceuticals position peaked at $28.1K in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on FWL Investment Management's 13F filing for Q1 2026, filed 15 May 2026.